Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease-Reference-Cited by-同舟云学术

Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease

Published:2019-07-30 Issue:9 Volume:34 Page:1354-1364
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord

Author:

Mollenhauer Brit¹,Caspell‐Garcia Chelsea J.²,Coffey Christopher S.²,Taylor Peggy³,Singleton Andy⁴,Shaw Leslie M.⁵,Trojanowski John Q.⁶⁷,Frasier Mark⁸,Simuni Tanya⁹,Iranzo Alex¹⁰,Oertel Wolfgang¹¹,Siderowf Andrew⁷¹²,Weintraub Daniel¹²,Seibyl John¹³,Toga Arthur W.¹⁴,Tanner Caroline M.¹⁵,Kieburtz Karl¹⁶,Chahine Lana M.¹⁷,Marek Kenneth¹³,Galasko Douglas¹⁸,

Affiliation:

1. Department of NeurologyUniversity Medical Center Goettingen, Göttingen, Germany; and Paracelsus‐Elena Klinik Kassel Germany

2. Department of Biostatistics, College of Public HealthUniversity of Iowa Iowa City, Iowa USA

3. BioLegend Inc. San Diego, California USA

4. Molecular Genetics Section, Laboratory of NeurogeneticsNational Institute on Aging, National Institutes of Health Bethesda Maryland USA

5. Department of Pathology & Laboratory MedicinePerelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA

6. Center for Neurodegenerative Disease ResearchInstitute on Aging, Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA

7. Morris K. Udall Center of Excellence for Parkinson's Disease ResearchPerelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA

8. The Michael J. Fox Foundation for Parkinson's Research New York New York USA

9. Parkinson's Disease and Movement Disorders CenterNorthwestern University Feinberg School of Medicine Chicago Illinois USA

10. Neurological ServiceHospital Clinic de Barcelona Barcelona Spain

11. Department of NeurologyPhilipps University Marburg Marburg Germany

12. Department of Neurology Perelman School of MedicineUniversity of Pennsylvania Philadelphia Pennsylvania USA

13. Institute for Neurodegenerative Disorders New Haven Connecticut USA

14. University of Southern CaliforniaLaboratory of Neuro Imaging Los Angeles California USA

15. Department of NeurologyUniversity of California San Francisco San Francisco California USA

16. Clinical Trials Coordination CenterUniversity of Rochester Medical Center Rochester New York USA

17. Department of NeurologyUniversity of Pittsburgh Pittsburgh Pennsylvania USA

18. Department of NeurosciencesUniversity of California San Diego, San Diego, California USA

Funder

AbbVie

Avid Radiopharmaceuticals

Biogen Idec

Bristol-Myers Squibb

GE Healthcare

Genentech

GlaxoSmithKline

H. Lundbeck A/S

Merck

Michael J. Fox Foundation for Parkinson's Research

Pfizer

UCB

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.27806

Reference42 articles.

1. Parkinson's Disease Is Not Simply a Prion Disorder

2. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

3. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

4. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

5. Association of cerebrospinal fluid β‐amyloid 1‐42, T‐tau, P‐tau181, and α‐synuclein levels with clinical features of drug‐naive patients with early Parkinson disease;Kang JH;JAMA Neurol,2013

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease;Journal of Neurology;2024-09-09

2. Association between air pollution and cerebrospinal fluid alpha-synuclein in urban elders: the CABLE study;Frontiers in Aging Neuroscience;2024-08-30

3. Plasma level of alpha-synuclein oligomers as a biomarker for isolated rapid eye movement sleep behavior disorder diagnosis and progression: a prospective cohort study;Frontiers in Neurology;2024-08-23

4. The role of ADAR editing and nonsense-mediated decay in Parkinson’s Disease;2024-05-21

5. Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease;npj Parkinson's Disease;2024-05-17